• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    2/3/22 12:40:55 PM ET
    $AIH
    $APM
    $ARDS
    $BCDA
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

     

    Gainers

    • SOC Telemed (NASDAQ:TLMD) shares increased by 333.5% to $2.79 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 19.4 million, which is 2708.2% of its average full-day volume over the last 100 days. The company's market cap stands at $281.4 million.
    • BioCardia (NASDAQ:BCDA) stock rose 30.57% to $2.05. BioCardia's stock is trading at a volume of 52.3 million shares as of 12:30 EST. This is 33155.1% of its average full-day volume over the last 100 days. The company's market cap stands at $34.5 million.
    • Aptorum Group (NASDAQ:APM) stock moved upwards by 21.97% to $2.22. Aptorum Group's stock is trading at a volume of 934.0K shares as of 12:30 EST. This is 36.6% of its average full-day volume over the last 100 days. The company's market cap stands at $79.0 million.
    • Capricor Therapeutics (NASDAQ:CAPR) shares increased by 10.93% to $4.15. As of 12:30 EST, Capricor Therapeutics's stock is trading at a volume of 482.8K, which is 144.7% of its average full-day volume over the last 100 days. The company's market cap stands at $100.1 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) stock rose 9.45% to $2.2. As of 12:30 EST, this security is trading at a volume of 967.6K shares, making up 46.4% of its average full-day volume over the last 100 days. The company's market cap stands at $30.9 million.
    • Madrigal Pharmaceuticals (NASDAQ:MDGL) shares moved upwards by 8.43% to $67.12. Trading volume for Madrigal Pharmaceuticals's stock is 208.5K as of 12:30 EST. This is 104.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 billion.
    •  

    Losers

    • Palisade Bio (NASDAQ:PALI) shares fell 17.2% to $0.84 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 2.5 million shares, making up 346.8% of its average full-day volume over the last 100 days. The company's market cap stands at $11.4 million.
    • Kiromic BioPharma (NASDAQ:KRBP) shares decreased by 15.44% to $0.87. Trading volume for this security as of 12:30 EST is 348.5K, which is 236.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.4 million.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares declined by 13.4% to $2.65. The company's market cap stands at $62.5 million.
    • Mainz Biomed (NASDAQ:MYNZ) stock decreased by 12.17% to $12.35. Mainz Biomed's stock is trading at a volume of 64.8K shares as of 12:30 EST. This is 8.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $169.6 million.
    • Exicure (NASDAQ:XCUR) stock declined by 11.83% to $0.22. Trading volume for Exicure's stock is 23.7 million as of 12:30 EST. This is 341.6% of its average full-day volume over the last 100 days. The company's market cap stands at $23.4 million.
    • Surmodics (NASDAQ:SRDX) shares decreased by 10.41% to $41.3. The company's market cap stands at $577.1 million. As per the news, the Q1 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $APM
    $ARDS
    $BCDA

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/28/2026$964.00Overweight
    Barclays
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Surmodics Inc.
    $SRDX
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    Madrigal Pharmaceuticals Inc.
    $MDGL
    11/5/2025Neutral → Overweight
    Cantor Fitzgerald
    Madrigal Pharmaceuticals Inc.
    $MDGL
    11/3/2025$445.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $AIH
    $APM
    $ARDS
    $BCDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Madrigal Pharmaceuticals with a new price target

    Barclays initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $964.00

    1/28/26 7:18:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    SEC Filings

    View All

    Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    3/12/26 4:01:07 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Mainz Biomed N.V.

    PRE 14A - MAINZ BIOMED N.V. (0001874252) (Filer)

    3/12/26 9:24:51 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/11/26 4:00:01 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefitsSan Diego GMP manufacturing facility operational to support potential commercial launchCapricor uplisted to the Nasdaq Global Select MarketCash balance of approximately $318 million expected to support operations through 2027Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnol

    3/12/26 4:01:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

    Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017)Global Statistical Test (GST) composite endpoint showed significant overall treatment benefitDuchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression (p=0.018), consistent with mid-level (elbow) PUL v2.0 resultsDeramiocel BLA currently under FDA review with a PDUFA target action date of August 22, 2026 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treat

    3/12/26 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $AIH
    $APM
    $ARDS
    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 7:18:32 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:49:18 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Kelley Shannon T was granted 4,017 shares and sold $155,498 worth of shares (360 units at $431.94), increasing direct ownership by 43% to 12,138 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:34:05 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    Financials

    Live finance-specific insights

    View All

    Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

    – Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Thursday, March 12, 2026

    3/9/26 8:30:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports

    2/19/26 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

    Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in DuchenneDeramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experienceCompany plans to submit i

    12/3/25 7:20:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $APM
    $ARDS
    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

    SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

    11/14/24 4:46:40 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care